CoCites: A citation-based method for searching scientific literature

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham. Lancet Oncol 2017
Times Cited: 180

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Seung Tae Kim, Razvan Cristescu, Adam J Bass, Kyoung-Mee Kim, Justin I Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mijin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Mingew Choi, AmirAli Talasaz, Peter Soonmo Kang, Jonathan Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang. Nat Med 2018
Times Cited: 584

List of shared articles

Times cited

Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim. Biomedicines 2022

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.
Gianluca Businello, Valentina Angerilli, Sara Lonardi, Francesca Bergamo, Michele Valmasoni, Fabio Farinati, Edoardo Savarino, Gaya Spolverato, Matteo Fassan. Updates Surg 2022

Targeted therapy for upper gastrointestinal tract cancer: current and future prospects.
Matthew W Rosenbaum, Raul S Gonzalez. Histopathology 2021

Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.
Chengyi Mao, Xiaoxi Zeng, Chao Zhang, Yushang Yang, Xin Xiao, Siyuan Luan, Yonggang Zhang, Yong Yuan. Front Cell Dev Biol 2021

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y Janjigian, Kohei Shitara. Nat Rev Clin Oncol 2021

Targeted and immunotherapy in the era of personalised gastric cancer treatment.
Silvia Catanese, Florian Lordick. Best Pract Res Clin Gastroenterol 2021

The impact of recent next generation sequencing and the need for a new classification in gastric cancer.
Gianluca Businello, Francesca Galuppini, Matteo Fassan. Best Pract Res Clin Gastroenterol 2021

Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
Caroline Yk Fong, Ian Chau. Pharmacogenomics 2021

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Daniel V Catenacci, Joseph Chao, Kei Muro, Salah Eddin Al-Batran, Samuel J Klempner, Zev A Wainberg, Manish A Shah, Sun Young Rha, Atsushi Ohtsu, Astra M Liepa,[...]. Oncologist 2021

Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article.
Alexander R Siebenhüner, Sara De Dosso, Daniel Helbling, Christoforos Astaras, Petr Szturz, Peter Moosmann, Stefanie Pederiva, Thomas Winder, Philippe Von Burg, Markus Borner. Oncol Res Treat 2021

Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data.
Lionel Aurelien Kankeu Fonkoua, Harry H Yoon. Onco Targets Ther 2021

Genomic and Transcriptomic Characteristics of Esophageal Adenocarcinoma.
Sascha Hoppe, Christoph Jonas, Marten Christian Wenzel, Oscar Velazquez Camacho, Christoph Arolt, Yue Zhao, Reinhard Büttner, Alexander Quaas, Patrick Sven Plum, Axel Maximilian Hillmer. Cancers (Basel) 2021

Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View.
Justus Körfer, Florian Lordick, Ulrich T Hacker. Cancers (Basel) 2021

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives.
Nadja Niclauss, Ines Gütgemann, Jonas Dohmen, Jörg C Kalff, Philipp Lingohr. Cancers (Basel) 2021

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
Hannah Christina Puhr, Matthias Preusser, Gerald Prager, Aysegül Ilhan-Mutlu. Cancers (Basel) 2020

Progress and challenges in gastroesophageal cancer.
Olbia Serra, Elizabeth C Smyth, Florian Lordick. Curr Probl Cancer 2020

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients.
Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Whan Park, Neunggyu Park, Hukeun Lee, Sung Hee Hong, Song-Jae Lee, Seong-Won Song,[...]. Ther Adv Med Oncol 2020

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhening Zhang, Tong Xie, Xiaotian Zhang, Changsong Qi, Lin Shen, Zhi Peng. Chin J Cancer Res 2020

Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future.
Alessandro Parisi, Giampiero Porzio, Corrado Ficorella. Cancers (Basel) 2020

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Federica Papaccio, Marisol Huerta, Susana Roselló, Francisco Gimeno-Valiente, Desamparados Roda, Andrés Cervantes. J Clin Med 2020